India expected to see surge in Parkinson's disease, becoming 2nd-highest in 5 yrs: Experts at 6th International Annual Symposium-2026 in Kerala

India faces a surge in Parkinson's disease cases, potentially becoming second globally. Young-onset Parkinson's is a growing concern in Southeast Asia. Experts at a Kerala symposium highlighted the need for region-specific research and affordable treatments. Local manufacturing and international collaboration are key to expanding access to care for millions of patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ED1bohU
via IFTTT

Read More

Sun Pharma to stay disciplined on M&A, says Dilip Shanghvi

Sun Pharma plans a careful acquisition strategy. The company prioritizes organic growth to remain an attractive investment. Chairman Dilip Shanghvi highlighted a focus on innovative medicines in the US. Smaller acquisitions are being considered for emerging markets. The firm is also evaluating the biosimilar sector. This approach aims to strengthen long-term capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgdF51Y
via IFTTT

Read More

Battle for cooking oil: Nutritionists reveal which oil is best and what separates one from another

The battle for cooking oil has been heating up — with everything from coconut, mustard and refined oils fighting for shelf space, while avocado oil puts in an appearance now. ET asks experts whether any one oil can ever triumph over others.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/06hLabo
via IFTTT

Read More

Strengthening the India-US medicines partnership important: IPA

The Indian Pharmaceutical Alliance welcomed an interim trade agreement between India and the US, emphasizing that medicine security is crucial for national security. The pact aims to boost bilateral trade by reducing import duties on various goods, including generics, and offers Indian MedTech exporters a competitive edge in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z7RWUdD
via IFTTT

Read More

Wipro seeks Schedule M exemption for Tumkur plant, regulator to review plea

Wipro has sought relaxation in requirement of Schedule M for specific categories like disinfectants. The product, Maxkleen, has been registered as a drug. The company has asked to allow them to manufacture the product without a drug licence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VwMJ1gW
via IFTTT

Read More

Shukra Pharma gets YEIDA LoI for Rs 600-crore facility

Shukra Pharmaceuticals will establish a Rs 600-crore facility in Greater Noida. This plant will produce advanced surgical robotics and BNCT technology. The project aims to create over 900 direct jobs. A partnership with Borns Medical Robotics Inc. will bring surgical robotics to India. This venture seeks to make high-precision surgery affordable and accessible across India and Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SphfEqT
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Alembic Pharmaceuticals has secured a significant approval from the US health regulator. The company's generic version of Carbidopa, Levodopa, and Entacapone tablets, used for Parkinson's disease, has been cleared by the USFDA. This development marks a crucial step for Alembic in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qLcCkGV
via IFTTT

Read More